Selling cells: the economics of CAR-T therapy

As a new class of CAR-T cell therapies moves through clinical trials and the first of these innovative treatments enters the market, the therapy is causing almost as much consternation as excitement in the healthcare sphere. While CAR-T looks set to transform the treatment of cancer, what does the future hold for one of the industry’s most advanced – and expensive – treatments? Sally Turner finds out.

2018-10-01T12:24:18+01:00 23 October 2018|Health|